213 related articles for article (PubMed ID: 20592094)
1. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.
Radu GU; Caidi H; Miao C; Tripp RA; Anderson LJ; Haynes LM
J Virol; 2010 Sep; 84(18):9632-6. PubMed ID: 20592094
[TBL] [Abstract][Full Text] [Related]
2. Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.
Rey GU; Miao C; Caidi H; Trivedi SU; Harcourt JL; Tripp RA; Anderson LJ; Haynes LM
PLoS One; 2013; 8(12):e83075. PubMed ID: 24376637
[TBL] [Abstract][Full Text] [Related]
3. A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.
Boyoglu-Barnum S; Gaston KA; Todd SO; Boyoglu C; Chirkova T; Barnum TR; Jorquera P; Haynes LM; Tripp RA; Moore ML; Anderson LJ
J Virol; 2013 Oct; 87(20):10955-67. PubMed ID: 23885067
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.
Boyoglu-Barnum S; Chirkova T; Todd SO; Barnum TR; Gaston KA; Jorquera P; Haynes LM; Tripp RA; Moore ML; Anderson LJ
J Virol; 2014 Sep; 88(18):10569-83. PubMed ID: 24990999
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.
Caidi H; Harcourt JL; Tripp RA; Anderson LJ; Haynes LM
PLoS One; 2012; 7(12):e51485. PubMed ID: 23300550
[TBL] [Abstract][Full Text] [Related]
6. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
7. Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.
Han J; Takeda K; Wang M; Zeng W; Jia Y; Shiraishi Y; Okamoto M; Dakhama A; Gelfand EW
Am J Respir Cell Mol Biol; 2014 Jul; 51(1):143-54. PubMed ID: 24521403
[TBL] [Abstract][Full Text] [Related]
8. Lipopolysaccharide Inhibits FI-RSV Vaccine-enhanced Inflammation Through Regulating Th Responses.
Yin W; Li HY; Zheng BY; Deng YQ; Li WJ; Liu Y; Zeng RH
Curr Med Sci; 2019 Jun; 39(3):363-370. PubMed ID: 31209804
[TBL] [Abstract][Full Text] [Related]
9. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
[TBL] [Abstract][Full Text] [Related]
10. Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.
Lee JS; Kwon YM; Hwang HS; Lee YN; Ko EJ; Yoo SE; Kim MC; Kim KH; Cho MK; Lee YT; Lee YR; Quan FS; Kang SM
Vaccine; 2014 Oct; 32(44):5866-74. PubMed ID: 25173478
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
Haynes LM; Caidi H; Radu GU; Miao C; Harcourt JL; Tripp RA; Anderson LJ
J Infect Dis; 2009 Aug; 200(3):439-47. PubMed ID: 19545210
[TBL] [Abstract][Full Text] [Related]
12. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
13. Experimental animal model for analyzing immunobiological responses following vaccination with formalin-inactivated respiratory syncytial virus.
Sawada A; Nakayama T
Microbiol Immunol; 2016 Apr; 60(4):234-42. PubMed ID: 26865035
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine.
Tripp RA; Anderson LJ
J Virol; 1998 Nov; 72(11):8971-5. PubMed ID: 9765442
[TBL] [Abstract][Full Text] [Related]
15. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.
Miao C; Radu GU; Caidi H; Tripp RA; Anderson LJ; Haynes LM
J Gen Virol; 2009 May; 90(Pt 5):1119-1123. PubMed ID: 19264600
[TBL] [Abstract][Full Text] [Related]
16. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
[TBL] [Abstract][Full Text] [Related]
17. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
Johnson TR; Parker RA; Johnson JE; Graham BS
J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
[TBL] [Abstract][Full Text] [Related]
18. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
[TBL] [Abstract][Full Text] [Related]
20. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern.
Waris ME; Tsou C; Erdman DD; Zaki SR; Anderson LJ
J Virol; 1996 May; 70(5):2852-60. PubMed ID: 8627759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
